We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more call options, than puts

Call options by funds: $21.9M | Put options by funds: $12.3M

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

16% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 31

2% more funds holding

Funds holding: 228232 (+4)

9% less repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 85

19% less capital invested

Capital invested by funds: $5.13B → $4.15B (-$971M)

Holders
232
Holders Change
+4
Holders Change %
+1.75%
% of All Funds
5.17%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
36
Increased
77
Reduced
85
Closed
31
Calls
$21.9M
Puts
$12.3M
Net Calls
+$9.55M
Net Calls Change
-$5.66M
Name Holding Trade Value Shares
Change
Change in
Stake
Federated Hermes
51
Federated Hermes
Pennsylvania
$11.6M +$2.65M +17,433 +27%
EVM
52
Eaton Vance Management
Massachusetts
$10.7M +$11.6M +76,488 New
Morgan Stanley
53
Morgan Stanley
New York
$10.4M -$2.05M -13,489 -15%
AIC
54
AWM Investment Company
New York
$9.8M
Deutsche Bank
55
Deutsche Bank
Germany
$9.75M -$30.9M -203,849 -75%
SIM
56
Spark Investment Management
New York
$9.54M
Macquarie Group
57
Macquarie Group
Australia
$9.53M
Bank of America
58
Bank of America
North Carolina
$9.43M +$3.1M +20,450 +44%
TCIM
59
TIAA CREF Investment Management
New York
$9.32M -$220K -1,448 -2%
Axa
60
Axa
France
$8.67M
American Century Companies
61
American Century Companies
Missouri
$8.41M -$165K -1,088 -2%
Massachusetts Financial Services
62
Massachusetts Financial Services
Massachusetts
$8.09M +$184K +1,213 +2%
AA
63
ALPS Advisors
Colorado
$7.99M +$473K +3,114 +6%
TA
64
Teachers Advisors
New York
$7.67M +$274K +1,805 +3%
Citigroup
65
Citigroup
New York
$7.65M +$7.34M +48,333 +769%
New York State Common Retirement Fund
66
New York State Common Retirement Fund
New York
$7.45M +$3.21M +21,161 +66%
PNC Financial Services Group
67
PNC Financial Services Group
Pennsylvania
$6.27M -$599K -3,943 -8%
USAA
68
United Services Automobile Association
Texas
$6.24M -$1.99M -13,107 -23%
TD Asset Management
69
TD Asset Management
Ontario, Canada
$5.96M -$432K -2,846 -6%
California State Teachers Retirement System (CalSTRS)
70
California State Teachers Retirement System (CalSTRS)
California
$5.9M +$144K +949 +2%
Wells Fargo
71
Wells Fargo
California
$5.67M +$3.03M +19,959 +97%
AIM
72
ARK Investment Management
Florida
$5.66M +$6.14M +40,440 New
Swiss National Bank
73
Swiss National Bank
Switzerland
$5.66M +$197K +1,300 +3%
California Public Employees Retirement System
74
California Public Employees Retirement System
California
$5.58M -$455K -3,000 -7%
RhumbLine Advisers
75
RhumbLine Advisers
Massachusetts
$5.29M +$2.05M +13,524 +56%

LOXO Hedge Fund Activity: Q4 2018 in Review

232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.

  • 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
  • Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
  • 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
  • The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
  • The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.

Based on aggregated 13F filings for Q4 2018.